In 2004, the FDA issued a written warning to Merck about false and misleading statements about Fosamax® in some of its advertising and marketing materials, and demanded removal of all misleading statements. The FDA also urged Merck to make certain Fosamax® labeling changes, and in fact, Merck did make some labeling changes, but not until more than six months after the FDA communication—and there remains some question as to whether or not the changes were adequate. fosamax cancer      fosamax throat cancer      All     
  • Family
  • Discuss
  • Add To 

Who Voted for this Story


Log in to comment or register here.
Advanced Search  •  RSS Feeds  •  Contact Us  •  Privacy Policy  •  Terms Of Use  •  ^ To Top